IP Library Patent Application 18496573
Patent Application
App. No. 18/496,573

END-TO-END CELL THERAPY AUTOMATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/496,573
Abstract

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Claims (11)

1 . An automated cell engineering system comprising:

a) an outer shell comprising a plurality of separate chambers configured to activate, expand, concentrate and harvest a cell culture,

wherein one of the chambers comprises an electroporation unit, and one of the chambers comprises a magnetic separation unit;

b) a self-contained, removable and replaceable cassette that includes a substantially non-yielding cell culture chamber;

c) at least two of a temperature sensor, a pH sensor, a glucose sensor, an oxygen sensor, a carbon dioxide sensor, and an optical density sensor configured to monitor a temperature, a pH, a glucose concentration, and oxygen level, a carbon dioxide level, and/or an optical density of a cell culture within the self-contained, removable and replaceable cassette,

wherein the automated cell engineering system is configured to be prefilled with an activation reagent, a vector, a cell culture media, nutrients, and a selection reagent, and wherein a first chamber of the separate chambers is maintained at a temperature of about 25° C. to about 37° C., and a second chamber is maintained at a temperature of about 4° C. to about 8° C.

2 . The system of claim 1 , further comprising a pump configured to drive fluid to and/or from the substantially non-yielding cell culture chamber in response to monitoring one or more of the temperature sensor, the pH sensor, the glucose sensor, the oxygen sensor, the carbon dioxide sensor, and the optical density sensor.

3 . The system of claim 1 , further comprising a user interface configured to receive user inputs.

4 . The system of claim 1 , further comprising a computer control system.

5 . The system of claim 1 , wherein the self-contained, removable and replaceable cassette comprises one or more sampling and/or injection ports.

6 . The system of claim 1 , wherein the substantially non-yielding cell culture chamber supports at least 2 billion cells.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2026
From: LONZA WALKERSVILLE, INC.; LONZA COLOGNE GMBH
To: OCTANE BIOTECH INC.
Reel/Frame 075379/0624 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: SHI, YALING; MCAFEE, ERIKA; BANDAPALLE, SAMATHA; O'CONNOR, JOSEPH; ABRAHAM, EYTAN
To: LONZA WALKERSVILLE, INC.
Reel/Frame 065391/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: SIEHOFF, ANN; GLEISSNER, TIMO
To: LONZA COLOGNE GMBH
Reel/Frame 065391/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2023
From: PURPURA, KELLY; TRAINOR, NUALA; SMITH, TIMOTHY
To: OCTANE BIOTECH INC.
Reel/Frame 065391/0295 →